Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders
Countries citing papers authored by Robert L. Avery
Since
Specialization
Citations
This map shows the geographic impact of Robert L. Avery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert L. Avery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert L. Avery more than expected).
This network shows the impact of papers produced by Robert L. Avery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert L. Avery. The network helps show where Robert L. Avery may publish in the future.
Co-authorship network of co-authors of Robert L. Avery
This figure shows the co-authorship network connecting the top 25 collaborators of Robert L. Avery.
A scholar is included among the top collaborators of Robert L. Avery based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Robert L. Avery. Robert L. Avery is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Giust, Jack, Alessandro Castellarin, Nathan Steinle, et al.. (2018). Treat and Extend Versus Bi-monthly dosing with Aflibercept for the Treatment of Diabetic Macular Edema, One Year Outcomes (EVADE Study). Investigative Ophthalmology & Visual Science. 59(9). 1957–1957.1 indexed citations
5.
Avery, Robert L. & Gabriel M. Gordon. (2018). Does Anti-VEGF Treatment for AMD Lower the Risk of Neovascularization in the Fellow Eye? A Meta-analysis. Investigative Ophthalmology & Visual Science. 59(9). 1474–1474.1 indexed citations
6.
Kashani, Amir H., Jane Lebkowski, Firas M. Rahhal, et al.. (2018). A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration. Science Translational Medicine. 10(435).266 indexed citations breakdown →
7.
Steinle, Nathan, Dilsher S. Dhoot, Carlos Quezada-Ruiz, et al.. (2015). Intravitreal Perfluoropropane Gas (C3F8) Versus Ocriplasmin for Vitreomacular Traction (VMT). Investigative Ophthalmology & Visual Science. 56(7). 3515–3515.1 indexed citations
8.
Eaton, Alexander M., et al.. (2015). In Vivo and In vitro Force Testing of a New Guarded Injection Device. Investigative Ophthalmology & Visual Science. 56(7). 393–393.1 indexed citations
9.
Steinle, Nathan, Carlos Quezada-Ruiz, Dante J. Pieramici, et al.. (2014). Outer Band Reflectivity Changes on SD-OCT Following Intravitreal Ocriplasmin for Vitreomacular Traction (VMT) and macular holes (MH). Investigative Ophthalmology & Visual Science. 55(13). 296–296.3 indexed citations
10.
Avery, Robert L., Alessandro Castellarin, Nathan Steinle, et al.. (2014). Systemic Pharmacokinetics Following Intravitreal Injections of Ranibizumab, Bevacizumab or Aflibercept in Patients with DME. Investigative Ophthalmology & Visual Science. 55(13). 586–586.2 indexed citations
Avery, Robert L., et al.. (2013). Meta-analysis examining the systemic safety profile of intravitreal ranibizumab injections in AMD, RVO and DME. Investigative Ophthalmology & Visual Science. 54(15). 1535–1535.3 indexed citations
Avery, Robert L., et al.. (2010). A Novel Implantable, Refillable Pump for Intraocular Drug Delivery. Investigative Ophthalmology & Visual Science. 51(13). 3799–3799.5 indexed citations
15.
Pieramici, Dante J., Robert L. Avery, Alessandro Castellarin, et al.. (2007). Ranibizumab for the Treatment of Macular Edema Associated With Perfused Central Retinal Vein Occlusions. Investigative Ophthalmology & Visual Science. 48(13). 313–313.
16.
Avery, Robert L., Dante J. Pieramici, Melvin Rabena, et al.. (2007). Intravitreal Bevacizumab (Avastin®) in the Surgical Treatment of Proliferative Diabetic Retinopathy. Investigative Ophthalmology & Visual Science. 48(13). 4031–4031.1 indexed citations
17.
Csaky, Karl G., et al.. (2007). Pharmacokinetics of Intravitreal Bevacizumab in Humans. Investigative Ophthalmology & Visual Science. 48(13). 4936–4936.9 indexed citations
Smiddy, William E. & Robert L. Avery. (1991). Posterior chamber IOL implantation with suboptimal posterior capsular support.. PubMed. 22(1). 16–9.12 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.